What Do Analysts Think About Puma Biotechnology (PBYI)?

Puma Biotechnology, Inc. (NASDAQ:PBYI) is one of the best affordable biotech stocks to invest in now. Puma Biotechnology, Inc. (NASDAQ:PBYI) reported its fiscal Q2 2025 results on August 7, with product revenue net for the quarter coming up to $49.2 million, up from $44.4 million in fiscal Q2 2024.

The product revenue net consisted solely of revenue from sales of NERLYNX, which is Puma Biotechnology, Inc.’s (NASDAQ:PBYI) first commercial product. Product revenue net in the first six months of 2025 was $92.3 million, up from $84.6 million in the same time period in 2024.

TD Cowen analyst Marc Frahm maintained a Hold rating on Puma Biotechnology, Inc. (NASDAQ:PBYI) on August 7 and set a price target of $4.00.

Furthermore, Gena Wang from Barclays maintained a Sell rating on Puma Biotechnology, Inc. (NASDAQ:PBYI) on August 8 and set a price target of $2.00.

Puma Biotechnology, Inc. (NASDAQ:PBYI) is a biopharmaceutical company involved in the acquisition and development of innovative products to treat different kinds of cancers.

The company’s focus is on the in-licensing drug candidates that are either in the process of or have already obtained initial clinical testing to treat cancer. It then endeavors to develop these drug candidates further for commercial use.

While we acknowledge the potential of PBYI to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PBYI and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.